Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Michael R. McDevitt is a research scientist in the Departments of Medicine and Radiology at Memorial Sloan-Kettering Cancer Center in New York. He specializes in the development and clinical translation of targeted radiolabeled drug constructs to treat cancer and other diseases. Radioconstructs are drugs that combine antibodies and radionuclides for therapeutic and imaging applications in the treatment of cancer. His research involves the investigation of new chemistry, radiochemistry, biological activity, pharmacokinetics, safety, stability and the translation of new constructs into the clinic. He has also been investigating novel nanomaterial-based constructs and incorporating these materials into drug design strategies. After receiving his PhD degree from Case Western Reserve University, in 1985, Dr. McDevitt worked in biotechnology and joined MSKCC in 1995. In 2004, he received a master’s degree in engineering from The City University of New York. He is also a member of MSKCC’s Brain Tumor Center and Nanotechnology Center.
Michael R. McDevitt Develop radionuclide-labeled antibody constructs that target antigens expressed on tumor and tumor vasculature as therapeutic and diagnostic agents for the treatment of cancer. Investigate the pharmacokinetic profile of carbon nanotube scaffolds as unique delivery platforms for tumor and tumor vascular radiotherapy and imaging applications. Investigate the chemistry and biology of novel functionalized nanomaterials as targeting vectors to improve the specific cellular delivery of siRNA. Translation of radiolabeled alpha-, beta-and positron-emitting drug constructs into the clinic.Develop and facilitate the routine clinical use of radionuclide generator systems.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals